Critica has appointed seasoned global commodities executive Hannah Badenach to its board in a move that looks to be less about finding minerals and more about selling them.
asserted
that → appoint → them
The appointment comes as the company pushes both of its key critical minerals projects towards commercial reality.
asserted
company → come → reality
The Hong Kong-based specialist brings more than 20 years of experience in commodity trading, marketing, offtake and financing, particularly in tin, tungsten and rare earths, exactly the suite of commodities in Critica’s portfolio.
asserted
specialist → base → portfolio
Ms Badenach’s resume seems tailor-made for the challenge.
asserted
resume → seem → challenge
She previously spent 13 years at global commodity trader Noble Resources, where her most recent role was executive director, Metals & Mongolia.
asserted
role → spend → Resources
In that position, she managed international trading activities and negotiated marketing, offtake, financing and prepayment arrangements.
asserted
she → manage → marketing
Her board experience also spans several listed and private resources companies, including Peak Rare Earths, Materra Metals and Xanadu Mines.
asserted
experience → span → Earths
‘As we advance Mt Lindsay and Jupiter, her commercial expertise and experience building commodity supply chains will be invaluable.
asserted
expertise → advance → chains
In a strong show of alignment, Ms Badenach intends to receive her non-executive director fees in equity, subject to shareholder approval.
asserted
Badenach → intend → approval
The appointment is effective from October 1st, with current director Jamie Byrde set to resign from the board on October 26th.
asserted
Byrde → set → 26th
Critica chairman Tim Lindley said: “We are delighted to welcome a Director of Hannah’s calibre to the Critica Board.
asserted
We → say → Board
Hannah has traded the commodities we intend to produce.
asserted
we → trade → commodities
She has a deep understanding of the tungsten, tin and rare earths markets and, importantly, the commercial mechanisms that protect and enhance shareholder value, from offtake structuring and pricing to prepayment, project financing and supply chain development.
asserted
that → have → prepayment
Her appointment looks particularly timely given the company’s recent run of form.
asserted
appointment → look → form
Just last week, a new scoping study for its Mt Lindsay tin-tungsten project in Tasmania delivered in spades, modelling a whopping pre-tax net present value of $1.42 billion and featuring an eye-catching 64.9 per cent internal rate of return.
asserted
study → deliver → return
The study forecasts pre-production capital at a modest $244.5 million.
asserted
study → forecast → million
Mt Lindsay isn’t Critica’s only project rounding the corner towards commercialisation.
asserted
Lindsay → round → commercialisation
The company recently produced its first high-purity mixed rare earth oxide sample from its Jupiter project in WA, grading a stellar 98.2 per cent total rare earth oxides.
asserted
company → produce → oxides
Critica says the sample, which contains a high concentration of valuable magnet rare earths, will now be put in front of strategic partners to kick off offtake discussions.
asserted
which → say → discussions
The market backdrop for Critica’s key commodities adds another layer of intrigue.
asserted
backdrop → add → intrigue
Western tungsten markets remain tight, with an S&P Global report pointing to a sizeable ex-China supply gap.
asserted
report → remain → gap
At the same time, China’s export controls and US defence procurement restrictions are expected to impact the supply of rare earths, making tungsten and rare earths commercial expertise particularly relevant as Western customers seek secure sources.
asserted
customers → expect → sources
With a billion-dollar study now on the table for Mt Lindsay and its first saleable product samples emerging from Jupiter, Critica seems to be firing on both cylinders.
asserted
Critica → emerge → cylinders
Appointing a commercial heavyweight such as Badenach, whose remuneration is tied directly to share price growth, looks like a calculated move to turn impressive study numbers and high-grade samples into binding offtake deals.
asserted
remuneration → appoint → deals
Is your ASX-listed company doing something interesting?
asserted
company → list → something
The Aporia
